民生证券股份有限公司 关于上海优宁维生物科技股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：民生证券股份有限公司 | 被保荐公司简称：优宁维 | | --- | --- | | 保荐代表人姓名：梁军 | 联系电话：（021）60876732 | | 保荐代表人姓名：蒋红亚 | 联系电话：（021）60876732 | 四、其他事项 | 报告事项 | 说明 | | --- | --- | | 1、保荐代表人变更及其理由 | 2023年3月4日，优宁维公告《关于变更保荐代 | | | 表人的公告》。卞进先生由于工作变动原因， | | | 无法继续担任优宁维持续督导保荐代表人， | | | 民生证券委派蒋红亚女士为优宁维持续督导 | | | 保荐代表人，继续履行保荐职责。该事项已于 | | | 2022年度持续督导报告中披露。 | | 2、报告期内中国证监会和本所对保荐机构或 | | | 者其保荐的公司采取监管措施的事项及整改 | 无 | | 情况 | | | 3、其他需要报告的重大事项 | 无 | （以下无正文） 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 上海优宁维生物科技股份有限公司（以下简称"公司"）于2022年11月10日与 上海国投资本管理有限公司、上海浦东引领区投资中心（有限合伙）、上海孚腾 私募基金管理有限公司、上海浦东私募基金管理有限公司、山东省国际信托股份 有限公司、观芮企业管理咨询（上海）合伙企业（有限合伙）共同签署了《上海 引领接力行健私募基金合伙企业（有限合伙）合伙协议》，与上述各方共同出资 设立上海引领接力行健私募基金合伙企业（有限合伙）（以下简称"引领接力行 健基金"），并已办理完成工商注册登记手续及私募投资基金备案手续。2023年5 月24日，上述各方与交银国际信托有限公司（以下简称"交银信托"）共同签署 了新的《上海引领接力行健私募基金合伙企业（有限合伙）合伙协议》，协议约 定交银信托新增认缴出资额10,000万元，引领接力行健基金出资额变更为70,310 万元。 上述对外投资事项具体内容详见公司分别于2022年11月11日、2022年11月15、 2022年12月21日、2023年5月25日披露于巨潮咨询网（htt ...

证券代码：301166 证券简称：优宁维 公告编号：2023-038 上海优宁维生物科技股份有限公司 关于股东减持期限届满暨后续减持计划的预披露公告 （一）股东本次减持股份实施情况 （二）股东本次减持计划实施前后持股情况 | 股东 名称 | 股份性质 | 本次变动前持有股份 股数(股) | 占总股本比例 | 本次变动后持有股份 股数(股) | 占总股本比例 | | --- | --- | --- | --- | --- | --- | | | | | (%) | | (%) | | 嘉信投资 | 合计持有股份 | 2,401,200 | 2.77% | 2,070,000 | 2.39% | | | 其中：无限售条件股份 | 2,401,200 | 2.77% | 2,070,000 | 2.39% | | | 有限售条件股份 | | | | | | 上凯投资 | 合计持有股份 | 2,500,000 | 2.88% | 2,151,100 | 2.48% | | | 其中：无限售条件股份 | 2,500,000 | 2.88% | 2,151,100 | 2.48% | | | 有限售条件股份 | | | ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2023-001 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | 媒体采访 业绩说明会 | | 类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 (电话会议) | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 2023 | 年 月 日 5 16 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | | 董事长、总经理 冷兆武 | | | 董事、董事会秘书、副总经理 祁艳芳 | | 上市公司接待 人员姓名 | 副总经理、财务总监 唐敏 | | | 独立董事 唐松 | | | 保荐代表人 梁军 | | | 1、冷董你好，公司业绩下滑，股价持续单边下跌，公司有何举措 | | | 实现公司市值稳定增长，使股东乐于投资本公司。 | | | 答：投资者您好！公司上市以来，围绕"两个极致"战略（一站式平 | | | 台极 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,195,124,205.48, representing a 7.70% increase compared to ¥1,109,667,928.51 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥106,485,089.72, a decrease of 2.06% from ¥108,728,231.17 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥85,186,859.38, down 16.45% from ¥101,963,311.26 in 2021[21]. - The net cash flow from operating activities was -¥143,302,138.95, a decline of 342.79% compared to ¥59,022,956.47 in 2021[21]. - Basic earnings per share decreased by 25.90% to ¥1.23 from ¥1.66 in 2021[21]. - The total assets at the end of 2022 were ¥2,478,722,776.83, an increase of 7.16% from ¥2,313,053,372.17 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were ¥2,157,515,929.23, up 3.32% from ¥2,088,255,081.32 at the end of 2021[21]. - The company achieved operating revenue of 1,195.12 million yuan, a year-on-year increase of 7.70%, and a net profit attributable to shareholders of 106.49 million yuan, a year-on-year decrease of 2.06%[60]. - The revenue from life science reagents accounted for 82.23% of total revenue, amounting to CNY 982,706,775.67, with a year-on-year growth of 7.21%[73]. R&D and Innovation - R&D expenditure in China has increased significantly, reaching ¥30,870 billion in 2022, with a compound annual growth rate of 11.60% from 2013 to 2022[33]. - The company is developing multiple new products, including Luminex detection kits and multi-fluorescence immunohistochemistry kits, aimed at enhancing market competitiveness[83]. - The company's R&D investment in 2022 amounted to ¥34,371,147.74, representing 2.88% of total revenue, an increase from 1.51% in 2021[85]. - The R&D team is focusing on developing monoclonal antibodies for various biomarkers, which is expected to enhance the company's product pipeline and market position[84]. - The company plans to enhance its own brand "Absin" and "LabEx" by increasing laboratory numbers and improving brand value[108]. Market Expansion and Strategy - The company plans to continue expanding its R&D capabilities with the operation of the Hangzhou R&D center and increased investments in existing centers[85]. - Market expansion efforts include entering three new international markets, aiming for a 15% increase in overseas sales by the end of 2023[114]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[114]. - The company plans to launch a new flagship product in Q3 2023, expected to contribute an additional 300 million yuan in revenue[115]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in AI-driven health solutions[117]. Corporate Governance - The company emphasizes transparency in information disclosure, ensuring timely and accurate communication with investors[125]. - The board of directors consists of 9 members, including 3 independent directors, meeting the legal requirements[124]. - The company has established a performance evaluation system linking senior management's performance directly to their compensation[125]. - The company has maintained a stable governance structure with no significant changes in voting rights or shareholder arrangements reported[132]. - The company is committed to continuous improvement in its corporate governance practices, as evidenced by the recent appointments and elections of board members[134]. Shareholder Relations and Dividends - The company plans to distribute a cash dividend of 9 RMB per 10 shares to all shareholders, based on a total of 86,666,668 shares[4]. - The total cash dividend accounted for 100% of the distributable profit of 213,440,815.13 yuan[164]. - The company has established a framework for compensating investors in case of losses due to unfulfilled commitments[191]. - The company will ensure compliance with all relevant laws and regulations regarding share transfers during the lock-up period[186]. - The company will publicly explain any failure to fulfill commitments and the reasons behind it in a timely manner[191]. Operational Efficiency - The company has developed a comprehensive supply chain system integrating procurement, customs clearance, warehousing, sales, and logistics, enhancing operational efficiency[70]. - The company has implemented a modernized logistics system with cold chain storage and transportation to meet the high preservation and transportation requirements of life science reagents[58]. - The company aims to improve operational efficiency, targeting a reduction in costs by 15% through process optimization initiatives[117]. - The company has implemented cost-control measures that are expected to improve operating margins by 5% in 2023[118]. - The company has established a strong communication and cooperation mechanism with upstream suppliers and downstream customers, fostering long-term partnerships[183]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report, indicating potential uncertainties in future developments[4]. - The company faces risks from intensified industry competition, which could impact market share and brand recognition[109]. - The risk of technical personnel turnover is highlighted as a critical factor for maintaining the company's competitive advantage in the life sciences reagent field, particularly in antibody reagents[112]. - The company has committed to enhancing its intelligent information platform to support decision-making and improve operational efficiency[108]. - The internal control system was updated and improved to effectively mitigate operational risks[170]. Employee Management - The company has a total of 688 employees, including 397 sales personnel, 117 technical staff, and 32 financial personnel[159]. - The company emphasizes a training program that includes new employee orientation, monthly cultural training, and skill enhancement for management[161]. - The company has established a talent incentive mechanism, including performance assessments and stock option incentives, to enhance employee motivation[179]. - The company provides various employee benefits, including transportation, communication, and meal subsidies, to enhance employee satisfaction and loyalty[180]. - The company has a commitment to protecting shareholder rights and ensuring transparent information disclosure[179].

Financial Performance - The company's revenue for Q1 2023 was ¥274,133,939.07, representing a 13.48% increase compared to ¥241,570,107.45 in the same period last year[5] - Net profit attributable to shareholders decreased by 17.51% to ¥17,923,954.65 from ¥21,729,548.27 year-on-year[5] - The net profit after deducting non-recurring gains and losses dropped by 49.75% to ¥10,689,047.45 compared to ¥21,270,554.18 in the previous year[5] - Net profit for Q1 2023 was CNY 1,462,906.77, a decrease of 91.8% from CNY 17,923,954.65 in Q1 2022[19] - Basic and diluted earnings per share for Q1 2023 were CNY 0.20, down from CNY 0.25 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 64.71%, reaching -¥43,379,128.98, compared to -¥122,932,770.01 in the same period last year[5] - Cash and cash equivalents at the end of the period were $568,583,249.12, down from $982,045,717.77 in the previous period[23] - Cash flow from financing activities resulted in a net outflow of -$1,253,683.32, with no cash inflow reported[23] - Total cash outflow for operating activities was $337,764,835.83, a decrease of 8.4% from $368,642,283.66 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,445,456,102.29, a decrease of 1.34% from ¥2,478,722,776.83 at the end of the previous year[5] - Total liabilities decreased to CNY 270,508,475.55 from CNY 321,206,847.60, a reduction of 15.8%[16] - The company's equity attributable to shareholders increased to CNY 2,174,947,626.74 from CNY 2,157,515,929.23, an increase of 0.8%[16] Research and Development - R&D expenses surged by 193.53% to ¥12,957,737.52, reflecting increased investment in research platform development[9] - Research and development expenses increased significantly to CNY 12,957,737.52, compared to CNY 4,414,388.06 in the previous year, reflecting a growth of 193.5%[17] Government Support - The company received government subsidies amounting to ¥3,679,189.46, a significant increase of 696.15% compared to ¥462,120.98 in the previous year[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,475, indicating a stable shareholder base[11] Market and Product Development - The company is focusing on expanding its market presence and developing new products and technologies, although specific figures were not disclosed in the report[13] - The company has not reported any significant mergers or acquisitions in the first quarter of 2023[13] Other Financial Metrics - The weighted average return on equity fell to 0.49% from 1.04% year-on-year, indicating a decline in profitability[5] - The company reported a significant increase in investment income, which rose by 2436.25% to ¥1,109,611.31 from ¥43,750.00 in the previous year[9] - The company reported a fair value change gain of CNY 4,828,783.23, compared to CNY 399,891.16 in the previous year[19] - Other comprehensive income after tax for Q1 2023 was a loss of CNY 492,257.14, compared to a loss of CNY 15,433.67 in Q1 2022[19]

证券代码：301166 证券简称：优宁维 公告编号：2023-028 上海优宁维生物科技股份有限公司 关于召开 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"）定于 2023 年 5 月 16 日（星期二）15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网 "投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。出席本次说明会的人员有：公司 董事长、总经理冷兆武先生，董事会秘书祁艳芳女士、财务负责人唐敏女士、独 立董事唐松先生、保荐代表人梁军先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 15 日（星期一）17：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度业绩说明会上， ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-039 | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-038 | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-037 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...